Hepatitis C News and Research

Latest Hepatitis C News and Research

The state of sexually transmissible and blood-borne infections in Australia: the 2010 Surveillance Reports

Australia last year reported its largest number of new HIV cases since the early 1990s but has seen a reduction in cases of hepatitis, infectious syphilis and gonorrhoea, new data contained in HIV, viral hepatitis and sexually transmissible infections in Australia Annual Surveillance Report 2010 shows.

18 Oct 2010

BARACLUDE sNDA receives FDA approval for treatment of CHB patients with decompensated liver disease

Bristol-Myers Squibb Company announced today that the U.S. Food and Drug Administration (FDA) has approved the supplemental New Drug Application (sNDA) of BARACLUDE for the treatment of chronic hepatitis B (CHB) in adult patients with decompensated liver disease.

18 Oct 2010

NanoViricides' President delivers speech at ASNM Second Annual Conference

NanoViricides, Inc. announced today that the Company President was invited to and presented a talk at the Second Annual Conference of the American Society for NanoMedicine (ASNM).

18 Oct 2010

Nektar presents data of NKTR-181 mu-opioid analgesic candidate at Pain 2010 Symposium

Nektar Therapeutics presented promising data today from preclinical studies of NKTR-181, a next-generation mu-opioid analgesic candidate with a novel molecular design. NKTR-181 is being developed to effectively treat pain while addressing the abuse liability and serious side effects associated with traditional opioid therapies.

18 Oct 2010

Bioniche's research scientists give presentations at Modern Vaccine and Adjuvant Formulation Conference

Bioniche Life Sciences Inc. a research-based, technology driven Canadian biopharmaceutical company, today announced that two of its senior research scientists gave presentations at the Modern Vaccine and Adjuvant Formulation Conference in Cannes, France this week.

18 Oct 2010

Nektar presents NKTR-181 preclinical data at ASA 2010 Annual Meeting

Nektar Therapeutics today presented new preclinical data demonstrating that NKTR-181, a mu-opioid analgesic with a novel molecular structure, dramatically reduces abuse liability while providing analgesia comparable to oxycodone and morphine.

18 Oct 2010

Royal Cornwall Hospital receives grant to study Hepatitis E

Researchers from the Royal Cornwall Hospital in Truro have received a grant of -337,000 to carry out a two-year study with partners in Glasgow and Norwich into a rare form of Hepatitis - Hepatitis E. The grant has come from the Chief Scientist's Office for Scotland and will be divided between the three centres taking part in the study.

18 Oct 2010

Anadys prices underwritten public offering of common stock

Anadys Pharmaceuticals, Inc. announced today the pricing of its underwritten public offering of 13,888,889 shares of its common stock at a price to the public of $1.80 per share. The gross proceeds to Anadys from this offering are expected to be approximately $25.0 million, before deducting underwriting discounts and commissions and other estimated offering expenses.

15 Oct 2010

Enrollment complete in Inhibitex's FV-100 Phase II clinical trial in shingles patients

Inhibitex, Inc., announced today that it has completed enrollment in a Phase II clinical trial of FV-100 in shingles (herpes zoster) patients. The objectives of the trial are to further evaluate the safety of FV-100 and its potential therapeutic benefit in reducing the severity and duration of shingles-associated pain, the incidence of post herpetic neuralgia (PHN), and the time to heal shingles-related lesions.

15 Oct 2010

WHO Western Pacific meeting addresses immunization, TB control, women's health

The WHO Regional Committee for the Western Pacific meeting continued with leaders discussing regional immunization goals, public health emergencies, TB control, and the health effects of urbanization, multiple news outlets report.

15 Oct 2010

FibroGen announces initiation of FG-3019 phase 2 study for reversing liver fibrosis

FibroGen, Inc. today announced initiation of a phase 2 study to compare the efficacy of FG-3019, a human monoclonal antibody against connective tissue growth factor (CTGF), with placebo in reversing liver fibrosis (scarring of the liver) due to chronic infection with hepatitis B virus (HBV).

15 Oct 2010

NanoViricides files financial year end annual report with SEC

NanoViricides, Inc. reports that it has filed its financial year end annual report (Form 10K) with the Securities and Exchange Commission (SEC) yesterday in a timely manner.

14 Oct 2010

Study confirms long term survival benefit of ELAD bioartificial liver support system in Chinese ACLF patients

Vital Therapies, Inc., today announced that a poster is being presented at the American Association for the Study of Liver Diseases (AASLD) meeting in Boston on Tuesday, November 2nd. It confirms that previously reported findings of improved transplant free survival (TFS) in Chinese subjects with acute-on-chronic liver failure (ACLF) treated with the ELAD® bioartificial liver support system are maintained for up to three years.

14 Oct 2010

New evidence supports possible link between XMRV and prostate cancer

Xenotropic murine leukemia virus-related virus (XMRV) has been the subject of many studies since its discovery in 2006, but conflicting reports have created an unclear picture of XMRV's role in human disease. In three recent studies published in the November 15 issue of The Journal of Infectious Diseases, now available online, the evidence supports a possible link between XMRV and prostate cancer but not other links involving chronic fatigue syndrome, HIV infection, or hepatitis C virus (HCV) infection.

13 Oct 2010

QIAGEN, Abbott enter agreement to strengthen testing menus for automated in-vitro diagnostic applications

QIAGEN and Abbott today announced that they have entered into an agreement that significantly strengthens both companies' testing menus for automated in-vitro diagnostic applications in the United States and Canada. Financial terms were not disclosed.

From QIAGEN Manchester Limited 13 Oct 2010

COU-AA-301 Phase 3 study demonstrates improvement in CRPC survival rate

Results from a pre-specified interim analysis of a randomized, placebo-controlled Phase 3 study, COU-AA-301, demonstrate that patients treated with the investigational agent abiraterone acetate plus low-dose prednisone/prednisolone showed a significant improvement in overall survival compared to patients treated with prednisone/prednisolone plus placebo.

11 Oct 2010

'Achilles heel' for HCV infection

Scientists at the Gladstone Institute of Virology and Immunology (GIVI) have found that an enzyme associated with the storage of fat in the liver is required for the infectious activity of the hepatitis C virus (HCV). This discovery may offer a new strategy for treating the infection.

11 Oct 2010

NIAID awards $6.25M to Profectus to optimize portfolio of genetic adjuvants

Profectus BioSciences, Inc., a technology based vaccine company devoted to the treatment and prevention of chronic viral diseases, today announced that it has received $6.25M in National Institute of Allergy and Infectious Disease (NIAID) grants and contracts.

8 Oct 2010

Roche receives development and commercialization rights for danoprevir drug

InterMune, Inc. today announced that it has sold worldwide development and commercialization rights to danoprevir (also known as RG7227 or ITMN-191) to Hoffman-La Roche Inc. and F. Hoffman-La Roche Ltd. for $175 million in cash.

7 Oct 2010

Teen sex on the rise and so are STIs: Survey

A survey of 8,800 Australian year 10 and year 12 students in 300 schools around Australia was taken in three snapshots between 1997 and 2008. It was found that with the rise of risky alcohol consumption among Australia's teenagers there is also a surge of sex “under the influence” and number of sexual partners and unsafe and unprotected intercourse. However, the awareness of HIV/AIDS remained high.

6 Oct 2010

Hepatitis C News and Research

Latest Hepatitis C News and Research

The state of sexually transmissible and blood-borne infections in Australia: the 2010 Surveillance Reports

BARACLUDE sNDA receives FDA approval for treatment of CHB patients with decompensated liver disease

NanoViricides' President delivers speech at ASNM Second Annual Conference

Nektar presents data of NKTR-181 mu-opioid analgesic candidate at Pain 2010 Symposium

Bioniche's research scientists give presentations at Modern Vaccine and Adjuvant Formulation Conference

Nektar presents NKTR-181 preclinical data at ASA 2010 Annual Meeting

Royal Cornwall Hospital receives grant to study Hepatitis E

Anadys prices underwritten public offering of common stock

Enrollment complete in Inhibitex's FV-100 Phase II clinical trial in shingles patients

WHO Western Pacific meeting addresses immunization, TB control, women's health

FibroGen announces initiation of FG-3019 phase 2 study for reversing liver fibrosis

NanoViricides files financial year end annual report with SEC

Study confirms long term survival benefit of ELAD bioartificial liver support system in Chinese ACLF patients

New evidence supports possible link between XMRV and prostate cancer

QIAGEN, Abbott enter agreement to strengthen testing menus for automated in-vitro diagnostic applications

COU-AA-301 Phase 3 study demonstrates improvement in CRPC survival rate

'Achilles heel' for HCV infection

NIAID awards $6.25M to Profectus to optimize portfolio of genetic adjuvants

Roche receives development and commercialization rights for danoprevir drug

Teen sex on the rise and so are STIs: Survey

Exploring the G:Box and for high-quality imaging

Shaping the Future of Neuroscience: A Conversation with Atlas Antibodies on the MolBoolean™ and the Impact of SfN 2024

How the Arts Reshape Brain Function: Susan Magsamen on the Future of Neuroaesthetics

Hepatitis C News and Research

Latest Hepatitis C News and Research

Exploring the G:Box and for high-quality imaging

Shaping the Future of Neuroscience: A Conversation with Atlas Antibodies on the MolBoolean™ and the Impact of SfN 2024

How the Arts Reshape Brain Function: Susan Magsamen on the Future of Neuroaesthetics

Newsletters you may be interested in